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Abstract: Some tissues, such as the adult human hearts, are unable to adequately regenerate
after damage.  Strategies in tissue engineering (TE) propose innovations to assist the
body in recovery and repair.  For example, TE approaches may be able to attenuate
heart remodeling after myocardial infarction.  As with any functional tissue, successful
regeneration involves the proper delivery of specific cell types (cardiomyocytes,
endothelial-cells, and most likely smooth-muscle-cells, as well as cardiac-fibroblasts)
and environmental cues favoring integration and survival.  Engineered cardiac-tissues
address elements of soluble signals, cell-to-cell interactions or the use of extracellular
matrix materials as delivery vehicles, where other techniques of cell injection ignore
these tenants.  To date, a patch design combining these ingredients has yet to be
examined due to various levels of difficulty in manipulation of the engineered materials.
We have developed a method of patch construction that combines cell-encapsulation,
cell-sheet-engineering, as well as, the use of natural fibrous matrices for the purpose of
delivering cells for tissue regeneration.  We demonstrate that cells with pre-established
cell-to-cell interaction, in a sheet can be integrated into this construction.  Our Patch
architecture provides a nutrition rich protective environment permissive of allowing
cellular retention.  This patch design can be applied to other organs other than heart
with minimal design and material changes, and is meant to be a quickly built, off-the-
shelf product for regenerative therapies.  This protocol has five detailed steps.  First we
use the temperature-sensitive Poly(N-isopropylacrylamide) pNIPAAM to coat our tissue
culture dishes.  Then we culture our tissue specific cells on the surface of those plates
to form cell-sheets with strong lateral adhesions.  Thirdly, we create a base for the
patch by combining porous matrix with neo-permissive hydrogels and endothelial cells.
Finally, we lift the cell-sheets from the pNIPAAM coated dishes and transfer the sheet
to the base element, making the complete construct.
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April 2, 2013 
 
 
Dear Editor, 
 
Please find an attached manuscript by W.S. Turner et al, titled “Tissue Engineering:  Construction of a 
Multicellular 3D Scaffold for the Delivery of Layered Cell Sheets and Matrix,” which we feel would be a 
superb candidate for publication in the Journal of Visualized Experiments.  This original submission relates our 
technique for construction of a tissue engineering patch that can be applied to solid organs of the body.  The 
patch is unique in its ability to offer a shelter for protecting cells in a nutrient rich environment as well as 
organizing multiple cell types into unique patterns. 
 
Thank you for your consideration.  We look forward to hearing your impressions. 
 
 
Sincerely,  
 
William S. Turner, Ph.D. 
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Short Abstract:  
The assembly of multiple materials and cell types into a composite “patch” is necessary 
to recapitulate highly organized structures, such as heart and muscle.  Injection of cells 
and/or single materials alone has shown variable success in other organ systems and 
limited success in cardiac regeneration.
1-7
  Currently, stem cell-derived cells are delivered 
to damaged tissue using a variety of delivery methods including: direct cell injection, 
coronary artery perfusion (for the case of the heart), and multiple material carriers like 
hydrogels, synthetic polymers, and natural matrices.  Our method of patch construction is 
aimed at enhancing cell packaging by using a combination of cell sheet and materials-
based components for the delivery of both tissue specific functional cells and endothelial 
cells. This design combines strengths of both materials and multiple cell types.  The base 
fibrous matrix, provides the physical strength to the construct which is also filled with a 
neo-vessel permissive hydrogel with endothelial cells for establishing vascularization and 
integration of the cell sheets.   
Long Abstract:  
Some tissues, such as the adult human hearts, are unable to adequately regenerate after 
damage.
8,9
  Strategies in tissue engineering (TE) propose innovations to assist the body in 
recovery and repair.  For example, TE approaches may be able to attenuate heart 
remodeling after myocardial infarction (MI) and possibly increase total heart function to 
a near normal pre-MI level.
10
   As with any functional tissue, successful regeneration of 
cardiac tissue involves the proper delivery of specific cell types (cardiomyocytes, 
endothelial cells, and most likely smooth muscle cells, as well as cardiac fibroblasts) and 
environmental cues favoring integration and survival.  Engineered cardiac tissues address 
elements of soluble signals, cell-to-cell interactions or the use of extracellular matrix 
materials as delivery vehicles, where other techniques of cell injection ignore these 
tenants.9 ,11,12  To date, a patch design combining these ingredients have yet to be 
examined due to various levels of difficulty in manipulation of the engineered materials.  
Here, we have developed a method of patch construction that combines cell 
encapsulation, cell sheet engineering, as well as, the use of natural fibrous matrices for 
the purpose of delivering cells with the specific purpose of tissue regeneration.  
Furthermore, we demonstrate that cells with pre-established cell-to-cell interaction, in a 
sheet can be integrated into this construction.  Patch architecture is aimed at providing a 
nutrition rich protective environment permissive of allowing cellular retention.  This 
patch design can be applied to other organs other than heart with minimal design and 
material changes, and is meant to be a quickly built, off-the-shelf product for regenerative 
therapies.  This protocol has five detailed steps.  First we use the temperature sensitive 
Poly(N-isopropylacrylamide) pNIPAAM to coat our tissue culture dishes.  Then we 
culture our tissue specific cells on the surface of the coated plates to form sheets of cells 
with strong lateral adhesions.  Thirdly, we create a base for the patch by combining 
porous matrix with neo-permissive hydrogels and endothelial cells.  Finally, we lift the 
cell sheets from the pNIPAAM coated dishes and transfer the sheet to the base element, 
making the complete construct. 
Protocol Text: 
The overall production process for our layered cellular patch is outlined by the flowchart 
in Figure 1.  Here we use pNIPAAM-treated surfaces to culture muscle cells.  These 
cells are incubated at 37°C for a minimum of 24 hours at confluence to establish lateral 
connections between adjacent cells.  To release the cell sheet, the plate is subjected to 
temperatures below 32°C.  The cell sheet is then moved to the base matrix containing a 
neovascular-permissive hydrogel with vascular endothelial cells embedded into a 
stronger fibrous matrix.    
1.) Creation of pNIPAAM-coated plates 
1.01)   Weigh out 2.6 grams of pNIPAAM (Sigma-Aldrich) 
1.02)    Make a 60% toluene / 40% hexane (Sigma-Aldrich) solution 
 
1.03)    Dissolve the 2.6 grams of pNIPAAM in the 60%tolune/40%hexane solution. 
 
1.04)    Heat the mixture to 60°C. 
 
1.05)    Cut filter paper into a circle and place paper in the Buchner funnel. 
 
1.06)    Weigh a glass beaker. 
 
1.07)   Filter the solution through Buchner Funnel into the glass beaker (hexane will melt 
plastics) 
 
1.08)    Vacuum the beaker and contents overnight. 
 
Note: Until it is reacted with isopropyl it will oxidize so make sure it does not 
come into contact with oxygen. 
1.09)    Weigh the beaker to establish the weight of the pNIPAAM.   
 
1.10)   Add the same amount of isopropyl alcohol in weight as the pNIPAAM creating a   
50/50 solution. 
 
1.11)  Place the solution on surface to coat, allowing it to sit for 5 minutes under UV 
light. 
 
1.12)  Wash the plate with warm PBS 2x before use. 
2.)   Creation of Cell Sheets 
Note 1:  Cell sheets of primary cells for the target organ can be created using a number of 
different methods, or by coating tissue culture surfaces with thermo-responsive polymer 
as we have done here.  Pre-coated thermo-sensitive plates are also offered by a number of 
vendors.   
Note 2:  This protocol is for culture using a 35mm dish. 
2.01)  Isolate the cell population.  (This method is dependent on the individual derivation 
procedures and the type of muscle cells used.) Rat aortic smooth muscle cells 
(RAOSMC) are  used in this example.  These are primary smooth muscle cells isolated 
from the abdominal aorta of a rat and used below passage # 50 (Lonza). 
2.02)  Wash the cells with 2ml of warm PBS. 
2.03)  Add 3ml of trypsin for 5 minutes. 
2.04)  Inhibit trypsin by addition of culture media, or phosphate buffer solution (PBS) 
containing 10% Fetal Bovine Serum (FBS). 
2.05)  Count the cells. 
2.06)  Spin the cells at 1000rpm for 5min. 
2.07)  Aspirate the supernatant and resuspend the cells in SmGM2 plus bullet kit (Lonza) 
culture medium. 
2.08)  Place the media containing the cells on a 35ml thermo-sensitive plate – pNIPAAM 
coated plate at a concentration that will achieve 100% confluence.  For RAOSMCs we 
have determined that number to be 100,000 cells/cm
2
.  However, due to loss of cells 
during the passing, we use 120% of our final value. 
2.09)  Place into an incubator at 37C overnight. 
3.)  Preparation of Foundational Matrix 
3.01)  Various 3D fibrous matrices can be used to layer strong fibrous matrix between the 
delicate cell sheets.  Some examples include: gelfoam (Pfizer), bioglass, natural 
acellularized materials
13
 or nanospun materials
14,15
 The porcine urinary bladder matrix 
(UBM) used in these studies was generously provided from our collaborator, Dr 
Badylak.
16
  
3.02)  Prior to use, matrix characteristics should be determined including the lack of 
cellular content if decellularized matrix is used,
14,15
 cell specific viability, and void 
space.
17
 
3.03) Sterilize the fibrous matrix with 40 Gray (40 J/kg), over a 10 min period.
18
 
3.04)  Cut the matrix into a desired size and shape.  Here, we use a hole-punch to cut a 
4mm diameter circle. 
4.)  Seeding Endothelial Cells into a Neovascular Permissive Hydrogel 
4.01)  Endothelial cells can be obtained from primary variety of sources, including 
differentiation from stem or progenitor cells.  Here, we use HuVECs (Invitrogen). 
4.02)  Any permissive hydrogel can be used as long as the cross-linking time is short 
enough to allow the cells stay viable.  Here, we use HyStem (produced by Glycosan, a 
subsidiary of Biotime; Alameda, CA) 
4.03)  Preparation of the hydrogel is done in accordance with the company protocol. 
4.04)  Collect endothelial cells and disperse into a single cell solution using 1x trypsin 
(Accutase or Cell Dissociation Buffer could also be used for single cell dispersion) 
4.05)  Deactivate the trypsin enzyme by using an equal amount of soybean trypsin 
inhibitor or 10% FBS in PBS, collecting the solution/cells into a 15ml falcon tube. 
4.06)  Count the cells, and calculate the volume needed for the patch dimensions 
(previously quantified).  For a 4mm patch we will use 2 million endothelial cells. 
4.07)  Extract 2 million cells, and place into a new 15ml falcon tube. 
4.08)  Spin at (1000rpg) for 5 minutes. 
4.09)  Aspirate the supernatant, leaving the cells as a pellet in a falcon tube 
4.10)  Add 4/5 of the total volume desired from the 1:1 mixture of HyStem:Gelatin-S. 
4.11)  Resuspend the endothelial cells in the mixture 
4.12)  Place resuspended cells onto the base fibrous matrix cut in Step 2. 
4.13)  Add 1/5 of the total volume desired from the Extralink (crosslinker). 
4.14)  Incubate for 1 hour at 37C. 
5.  Isolation of Cell Sheets 
5.01)  Remove the 35mm pNIPAAM -treated plates from the incubator and place in a cell 
culture hood at room temperature. 
5.02)  Quickly remove the media from the cells, and add in 2ml of 6% gelatin that has 
been heated to 37°C.   
5.03)  While the gelatin is still warm, place the metal lattice into the gelatin, submerging 
it below the surface of the gelatin (Movie 1). 
5.04)  Place the plate onto ice for 5 to 7 minutes, allowing the gelatin to harden.   
5.05)  After 7 minutes, use a spatula to carefully ring the plate, and then use forceps to lift 
the metal lattice from the plate (the 6% gelatin, and the cell sheet should lift with the 
lattice)   
5.06)  Move the cell sheet to the dish with the based matrix with hydrogel, and carefully 
set the lattice on top of the construct.   (The apical side of the cell sheet will still be in the 
top position) 
5.07)  Add 2ml of warm media (37C). 
5.08)  Incubate overnight allowing the sheet of cells to adhere to the hydrogel surface, 
and remove the lattice after 24 hours 
Representative Figures and Results:   
The flow diagram (Figure 1) shows the overall method of making the multilayered patch.   
Cell sheets are detached from the pNIPAAM treated plate by dropping the temperature 
below 32°C.  Then the cell sheet is placed on top of the cross-linked hydrogel containing 
the endothelial cells seeded into the underlying fibrous matrix (Figure 1).  The pretreated 
thermo-sensitive plates (UpCell) can also be used for creating the cell sheets. Special 
topological surfaces  are used to specifically pattern (i.e. align) the cells
19
.   
The base fibrous matrix can be generated from decellularizing native tissue matrix or 
electronspun.  Here, we show the fibrous material sheet cut to a 4mm diameter for the 
patch base (Figure 2A).  The characterization of this material is important for 
determining the amount of hydrogel that can be used to fill the void spaces.  The matrix 
that we used here has been previously characterized and published.
17
 
The hydrogels containing endothelial cells are cross-linked after application of the 
HyStem liquid components to the fibrous matrix.   Fluorescence/transmission microscopy 
shows living cells stained with Calcien AM (Figure 2B) that have been captured in the 
cross-linked hydrogel. 
The process of creating the cell sheet is imaged (Figure 3), including comparison 
between our own pNIPAAM-coated plates and pre-coated plates purchased from a 
vendor, (UpCell plates; Nunc).  RAOSMC are plated on the pNIPAAM treated surface 
for at least 16 hours at 37C.  This minimum time allows the cells to establish their lateral 
boarder adhesions with neighboring cells (Figure 3A).  Note:  The cells must be at 
confluence to establish these lateral boarders.  After culturing for at least 16 hours, the 
plate of cells must be moved to room temperature for the a drop below 32°C, and using 
ice for 5-8 minutes speeds up the cooling process (Figure 3B) .  The temperature drop 
changes the conformational contact angle of the material coating allowing the cell sheet 
to lift off of the plate.  Figure 3C shows the cell sheet lifting from the plate.   
Plates coated in the laboratory worked well, after some optimization, for creating and 
moving the cell sheets.  Figure 4D shows a confluent monolayer of RAOSMC prior to 
transfer.  When the cells were allowed to lift, the sheets tended to fold and stick to itself 
(Figure 3E).  In fact, manipulating the cell sheets on pNIPAAM or purchased UpCell 
plates was difficult and often resulted in tearing of the sheets (Figure 3F).  Therefore, we 
needed to come up with a solution for transferring the sheets.  Once the cells are removed 
from the incubator and start to cool, 6% gelatin was used to cover the cells with an 
additional metal lattice embedded within the gel (Figure 3G).  As the plate cooled, the 
cells lifted, and the gelatin hardens.  Using forceps, the gelatin- lattice and cell sheet can 
be removed together from the culture plate; all at the same time (Figure 3H).  Then these 
three components are placed on top of the based construct (Figure 3I).  Here, the cell 
sheet (pink) is much larger than the underlying base matrix (thick white matrix under the 
pink cell sheet).  The cell sheet can easily be trimmed to size. 
The final cell patch (Figure 4) is created by layering the cell sheet onto the preformed 
complex of the patch base and permissive hydrogel.  From bottom to top, the patch 
consists of a fibrous matrix seeded with hyaluronan hydrogel containing the endothelial 
cells, and then the cell sheet is layered on top of this matrix.  Early attempts to 
manipulate the cell sheets without the use of the gelatin/lattice apparatus resulted in very 
small cell sheets that often folded and were torn (Figure 4A-D top down view).  Figure 
4A represents an early patch design composite picture combining the mitrotracker red 
dyed RAOSMC (Figure 4B), calcien AM green fluorescent HuVECs (Figure 4C), and 
the transmitted light image (Figure 4D).  Closer 10x images are supplied for the cell 
sheet and HA/Hydrogel without matrix (Figure 4E-H).  Figure 5E is the composite of 
the mitotraker red (Figure 4F), the Calcein AM green HuVECs (Figure 4G) and the 
transmitted light (Figure 4H).  The bottom up view (base matrix, HA/HuVEC), and cell 
sheet images of each component is show in Figures 5I-L.  The composite images is 
Figure 5I, with the individual parts represented in Figure 5J-L, Figure 4J shows the cell 
sheet (red), the endothelial cells (green) are in Figure 4K, and the transmission image 
(Figure 4L)  The composite image (Figure 4M) shows the patch with a uniform cell-
sheet covering the entire area of the matrix without any folding or tearing.  Figures 4M-P 
are also from the bottom looking up into the matrix.  Figure 4N is the cell sheet, 
containing Neutral Red.  Again, thick red strips appear around the matrix because the 
sheet folds in these areas directly adjacent to the edge of the matrix.  Transmission light 
imaging (Figure 4O) shows the morphology of the cells, and the structure of the matrix.   
Finally (Figure 4P), our matrix has a special quality of fluorescing at the same 
wavelength as Dapi.  Therefore we can use the ultraviolet excitation of the matrix to 
clearly separate it from the cell sheet (bright red).  The edges of the patch can be trimmed 
to remove any edges of the sheet that are hanging over the edges of the matrix. 
Tables and Figures:   
Figure 1:  Flow Chart.   PDMS plates are treated with pNIPAAM monomer solution.  
Then cell-sheets are created by seeding cells onto the surface of the coated plate.  The 
plate is kept at an incubation temperature of 37°C allowing the cells to reach confluence 
and establish lateral connections to neighboring cells.  Upon the drop in temperature, the 
pNIPAAM changes its conformation and become hydrophobic, thus allowing the cell 
sheet to detach (yellow disk).  Concurrently endothelial cells are captured in a 
neovascular permissive hydrogel (Glycosan HyStem-C from BioTime, Inc) by 
crosslinking the mixture after placing it upon the surface of the fibrous matrix (white 
disk).  The cell sheet is then transferred on top the combination (Matrix + Hydrogel) 
completing the construction of the patch. 
Figure 2:  A. The fibrous matrix is punched into a round shape 4mm in diameter to create 
small patches.  The endothelial cells are then embedded in the fibrous matrix using a 
hydrogel.  B.  HuVECs stained with mitotracker green (Calcein AM) suspended in HA 
hydrogels on the surface of the base matrix (10x). 
Figure 3:  Cell Lifting - Creation of Cell Sheets:  A. RAOSMC (1million) were 
cultured on Upcell-treated 35mm-dishes for 16 hours.  The cells are adherent to the 
surface at 37C. (10x) B. RAOSMC were lifted by placing the plate on ice for 5-7 
minutes. C. Edge of the lifted cell sheet created on UpCell surface (10x). D.  RAOSMC 
grown on 60/40 Hexan-Toluen/NIPAAM coated 35mm standard tissue culture plates. 
(4x) E.  When cooled, the cell sheets contracted and folded as they detached from the 
surface of the NIPAAM plate. (4x)  F. Due to the fragility of the single-cell sheet, the cell 
sheet often gets damage during lifting or other manipulations. (4x) G.  We, therefore, 
introduced a metal screen support to aid the transfer of the cell sheets.  Here, the 
RAOSMC - stained Neutral Red (Invitrogen) – were grown on a pNIPAAM coated plate 
and then lifted onto 6% gelatin with a porous metal screen support  H. and transferred to 
another plate without damage. (4x)  I.  The larger RAOSMC cell sheet layer (pink color) 
was then placed on top of the fibrous patch/hydrogel (arrow).  The metal screen can then 
be easily removed, washed, autoclaved, and reused. 
Figure 4:  Final Layered Cellular Patch:  Cells were cultured on a pNIPPAM coated 
surface and then moved as a sheet to the surface of the fibrous matrix.  Early trials that 
were not transferred with the gelatin/metal lattice resulted in small tattered patches (A-
D).  A.  Composite image of (B-D), RAOSMCs in two sheets stained with B. Mitotracker 
Red, with C. HuVECs stained with green, and D. in transmitted light. E.  Composite 
image of a cell-sheet combined with the matrix/HA-hydrogel containing Calceing AM 
stained HuVECs (green) F.  Red fluorescent RAOSMCs in a sheet.  G. Green fluorescent 
HuVECs suspended in a hydrogel.    H.  Transmission image of (E).  I. Composite image 
looking from the bottom of the patch upwards through the base matrix (not stained), HA 
containing HuVECs (green), and cell sheet of RAOSMCs (red), respectively.  J.  Red 
fluorescent RAOSMCs sheet, as seen through the matrix  K.  Green fluorescent HuVECs.    
L.  Transmission image of the patch construct.  M.  Composite picture of cell-sheets (red) 
over the base matrix (autofluorescent-blue). Cell sheets were maintained without tearing 
in making patches by implementing the use of the gelling/metal lattice construction 
technique.  N.  Cells in the sheet cover the base matrix, increased fluorescence at the 
edges is due to bunching of the cells.  O.  Transmission image of the construct.  P.  
Natural matrix is autofluorescent in the Dapi (blue wavelength). 
Discussion:  The method presented in this manuscript is a fairly low cost means of 
creating a cell sheet for the purpose of tissue engineering applications.  Creating 
pNIPAAM coated plates within a university laboratory can be standardized with this 
method.  The most significantly challenging component of this protocol centers on the 
manipulation of the cell sheet.  The cell sheet is rather fragile and will tear if manipulated 
with forceps.  Moreover, when the cell sheet is not held in place, it tends to contract.  The 
current construction allows for the use of multiple cell types and some organization.  The 
use of cell constructs (sheets) rather than single cells, may increase the likelihood of 
survival and integration for tissue engineered regenerative medicine applications.  It is 
now possible to work with implanting tissues rather than just the cells that make them up.  
Furthermore, this will allow scientist to study the nature of tissue structure in its 
importance for cell survival and function after implantation.  
Acknowledgments:  This work was funded by a New Faculty Award II from the 
California Institute of Regenerative Medicine (CIRM; RN2-00921-1), NIH-funded 
National Research Award (F32-HL104924), and CIRM Training Grant (TG21163).  
Materials were provided by:  Glycosan Biosystems Inc / BioTime and Dr. Stephen 
Badylak (University of Pittsburgh) 
Disclosures: I have nothing to disclose. 
Table of Specific Reagents and Equipment: 
Name of the 
reagent 
Company Catalogue number Comments (optional) 
Calcein-AM Invitrogen C3099 Cell tracker / live dye 
Lysotracker Red Invitrogen L7528 Cell tracker 
Neutral Red Sigma N7005 Visible Cell dye 
 
Supplementary Movie: 
The process by which we can transfer the sheets of cells is highlighted in the 
supplemental movie submitted with the document.   The movie shows, in step-wise 
process, the removal of the cells from the incubator; replacement of the media with 6% 
gelatin, the insertion of the metal screen, chilling of the cells on ice, transfer of the cells 
from the pNIPAAM coated dish to another dish, an image of the cells during transfer, and 
finally the removal of the screen from the sheet. 
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Table of Specific Reagents: 
Name of the 
reagent 
Company Catalogue number Comments (optional) 
Calcein-AM Invitrogen C3099 Cell tracker / live dye 
Lysotracker Red Invitrogen L7528 Cell tracker 
Neutral Red Sigma N7005 Visible Cell dye 
 
*Table of Reagents/ Materials Used
Click here to download Table of Reagents/ Materials Used: Table of Specific Reagents Final.docx 
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Title of Article:    
Author(s):   
 
Item 1 (check one box): The Author elects to have the Materials be made available (as described at 
http://www.jove.com/publish ) via:    Standard Access       Open Access 
 
Item 2 (check one box): 
 
 The Author is NOT a United States government employee. 
 The Author is a United States government employee and the Materials were prepared in the 
course of his or her duties as a United States government employee. 
 The Author is a United States government employee but the Materials were NOT prepared in the 
course of his or her duties as a United States government employee. 
 
 
ARTICLE AND VIDEO LICENSE AGREEMENT 
 
1.  Defined Terms.  As used in this Article and Video License 
Agreement, the following terms shall have the following 
meanings: “Agreement” means this Article and Video License 
Agreement; “Article” means the article specified on the last 
page of this Agreement, including any associated materials 
such as texts, figures, tables, artwork, abstracts, or summaries 
contained therein; “Author” means the author who is a 
signatory to this Agreement; “Collective Work” means a work, 
such as a periodical issue, anthology or encyclopedia, in which 
the Materials in their entirety in unmodified form, along with a 
number of other contributions, constituting separate and 
independent works in themselves, are assembled into a 
collective whole; “CRC License” means the Creative Commons 
Attribution-Non Commercial-No Derivs 3.0 Unported 
Agreement, the terms and conditions of which can be found 
at: http://creativecommons.org/licenses/by-nc-
nd/3.0/legalcode; “Derivative Work” means a work based 
upon the Materials or upon the Materials and other pre-
existing works, such as a translation, musical arrangement, 
dramatization, fictionalization, motion picture version, sound 
recording, art reproduction, abridgment, condensation, or any 
other form in which the Materials may be recast, transformed, 
or adapted; “Institution” means the institution, listed on the 
last page of this Agreement, by which the Author was 
employed at the time of the creation of the Materials; “JoVE” 
means MyJove Corporation, a Massachusetts corporation and 
the publisher of The Journal of Visualized Experiments; 
“Materials” means the Article and / or the Video; “Parties” 
means the Author and JoVE; “Video” means any video(s) made 
by the Author, alone or in conjunction with any other parties, 
or by JoVE or its affiliates or agents, individually or in 
collaboration with the Author or any other parties, 
incorporating all or any portion of the Article, and in which the 
Author may or may not appear. 
 
2.  Background.  The Author, who is the author of the Article, 
in order to ensure the dissemination and protection of the 
Article, desires to have the JoVE publish the Article and create 
and transmit videos based on the Article.  In furtherance of 
such goals, the Parties desire to memorialize in this Agreement 
the respective rights of each Party in and to the Article and the 
Video. 
 
3.  Grant of Rights in Article.  In consideration of JoVE agreeing 
to publish the Article, the Author hereby grants to JoVE, 
subject to Sections 4 and 7 below, the exclusive, royalty-free, 
perpetual (for the full term of copyright in the Article, 
including any extensions thereto) license (a) to publish, 
reproduce, distribute, display and store the Article in all forms, 
formats and media whether now known or hereafter 
developed (including without limitation in print, digital and 
electronic form) throughout the world, (b) to translate the 
Article into other languages, create adaptations, summaries or 
extracts of the Article or other Derivative Works (including, 
without limitation, the Video) or Collective Works based on all 
or any portion of the Article and exercise all of the rights set 
forth in (a) above in such translations, adaptations, 
summaries, extracts, Derivative Works or Collective Works and 
(c) to license others to do any or all of the above.  The 
foregoing rights may be exercised in all media and formats, 
whether now known or hereafter devised, and include the 
right to make such modifications as are technically necessary 
to exercise the rights in other media and formats.  If the “Open 
Access” box has been checked in Item 1 above, JoVE and the 
Author hereby grant to the public all such rights in the Article 
as provided in, but subject to all limitations and requirements 
set forth in, the CRC License. 
 
4.  Retention of Rights in Article.  Notwithstanding the 
exclusive license granted to JoVE in Section 3 above, the 
*Article & Video License Agreement
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Author shall, with respect to the Article, retain the non-
exclusive right to use all or part of the Article for the non-
commercial purpose of giving lectures, presentations or 
teaching classes, and to post a copy of the Article on the 
Institution’s website or the Author’s personal website, in each 
case provided that a link to the Article on the JoVE website is 
provided and notice of JoVE’s copyright in the Article is 
included.  All non-copyright intellectual property rights in and 
to the Article, such as patent rights, shall remain with the 
Author.   
 
5.  Grant of Rights in Video – Standard Access.  This Section 5 
applies if the “Standard Access” box has been checked in Item 
1 above or if no box has been checked in Item 1 above.  In 
consideration of JoVE agreeing to produce, display or 
otherwise assist with the Video, the Author hereby 
acknowledges and agrees that, Subject to Section 7 below, 
JoVE is and shall be the sole and exclusive owner of all rights of 
any nature, including, without limitation, all copyrights, in and 
to the Video.  To the extent that, by law, the Author is 
deemed, now or at any time in the future, to have any rights 
of any nature in or to the Video, the Author hereby disclaims 
all such rights and transfers all such rights to JoVE. 
 
6.  Grant of Rights in Video – Open Access.  This Section 6 
applies only if the “Open Access” box has been checked in 
Item 1 above.  In consideration of JoVE agreeing to produce, 
display or otherwise assist with the Video, the Author hereby 
grants to JoVE, subject to Section 7 below, the exclusive, 
royalty-free, perpetual (for the full term of copyright in the 
Article, including any extensions thereto) license (a) to publish, 
reproduce, distribute, display and store the Video in all forms, 
formats and media whether now known or hereafter 
developed (including without limitation in print, digital and 
electronic form) throughout the world, (b) to translate the 
Video into other languages, create adaptations, summaries or 
extracts of the Video or other Derivative Works or Collective 
Works based on all or any portion of the Video and exercise all 
of the rights set forth in (a) above in such translations, 
adaptations, summaries, extracts, Derivative Works or 
Collective Works and (c) to license others to do any or all of 
the above.  The foregoing rights may be exercised in all media 
and formats, whether now known or hereafter devised, and 
include the right to make such modifications as are technically 
necessary to exercise the rights in other media and formats.  
For any Video to which this Section 6 is applicable, JoVE and 
the Author hereby grant to the public all such rights in the 
Video as provided in, but subject to all limitations and 
requirements set forth in, the CRC License.  
 
7.  Government Employees.  If the Author is a United States 
government employee and the Article was prepared in the 
course of his or her duties as a United States government 
employee, as indicated in Item 2 above, and any of the 
licenses or grants granted by the Author hereunder exceed the 
scope of the 17 U.S.C. 403, then the rights granted hereunder 
shall be limited to the maximum rights permitted under such 
statute.  In such case, all provisions contained herein that are 
not in conflict with such statute shall remain in full force and 
effect, and all provisions contained herein that do so conflict 
shall be deemed to be amended so as to provide to JoVE the 
maximum rights permissible within such statute. 
 
8.  Likeness, Privacy, Personality.  The Author hereby grants 
JoVE the right to use the Author’s name, voice, likeness, 
picture, photograph, image, biography and performance in any 
way, commercial or otherwise, in connection with the 
Materials and the sale, promotion and distribution thereof.  
The Author hereby waives any and all rights he or she may 
have, relating to his or her appearance in the Video or 
otherwise relating to the Materials, under all applicable 
privacy, likeness, personality or similar laws. 
 
9.  Author Warranties.  The Author represents and warrants 
that the Article is original, that it has not been published, that 
the copyright interest is owned by the Author (or, if more than 
one author is listed at the beginning of this Agreement, by 
such authors collectively) and has not been assigned, licensed, 
or otherwise transferred to any other party. The Author 
represents and warrants that the author(s) listed at the top of 
this Agreement are the only authors of the Materials.  If more 
than one author is listed at the top of this Agreement and if 
any such author has not entered into a separate Article and 
Video License Agreement with JoVE relating to the Materials, 
the Author represents and warrants that the Author has been 
authorized by each of the other such authors to execute this 
Agreement on his or her behalf and to bind him or her with 
respect to the terms of this Agreement as if each of them had 
been a party hereto as an Author. The Author warrants that 
the use, reproduction, distribution, public or private 
performance or display, and/or modification of all or any 
portion of the Materials does not and will not violate, infringe 
and/or misappropriate the patent, trademark, intellectual 
property or other rights of any third party.  The Author 
represents and warrants that it has and will continue to 
comply with all government, institutional and other 
regulations, including, without limitation all institutional, 
laboratory, hospital, ethical, human and animal treatment, 
privacy, and all other rules, regulations, laws, procedures or 
guidelines, applicable to the Materials, and that all research 
involving human and animal subjects has been approved by 
the Author's relevant institutional review board. 
 
10.  JoVE Discretion.  If the Author requests the assistance of 
JoVE in producing the Video in the Author’s facility, the Author 
shall ensure that the presence of JoVE employees, agents or 
independent contractors is in accordance with the relevant 
regulations of the Author's institution.  If more than one 
author is listed at the beginning of this Agreement, JoVE may, 
in its sole discretion, elect not take any action with respect to 
the Article until such time as it has received complete, 
executed Article and Video License Agreements from each 
such author.  JoVE reserves the right, in its absolute and sole 
discretion and without giving any reason therefore, to accept 
or decline any work submitted to JoVE.  JoVE and its 
employees, agents and independent contractors shall have 
full, unfettered access to the facilities of the Author or of the 
Author’s institution as necessary to make the Video, whether 
actually published or not.  JoVE has sole discretion as to the 
method of making and publishing the Materials, including, 
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without limitation, to all decisions regarding editing, lighting, 
filming, timing of publication, if any, length, quality, content 
and the like. 
 
11.  Indemnification.  The Author agrees to indemnify JoVE 
and/or its successors and assigns from and against any and all 
claims, costs, and expenses, including attorney’s fees, arising 
out of any breach of any warranty or other representations 
contained herein.  The Author further agrees to indemnify and 
hold harmless JoVE from and against any and all claims, costs, 
and expenses, including attorney’s fees, resulting from the 
breach by the Author of any representation or warranty 
contained herein or from allegations or instances of violation 
of intellectual property rights, damage to the Author’s or the 
Author’s institution’s facilities, fraud, libel, defamation, 
research, equipment, experiments, property damage, personal 
injury, violations of institutional, laboratory, hospital, ethical, 
human and animal treatment, privacy or other rules, 
regulations, laws, procedures or guidelines, liabilities and 
other losses or damages related in any way to the submission 
of work to JoVE, making of videos by JoVE, or publication in 
JoVE or elsewhere by JoVE.  The Author shall be responsible 
for, and shall hold JoVE harmless from, damages caused by 
lack of sterilization, lack of cleanliness or by contamination 
due to the making of a video by JoVE its employees, agents or 
independent contractors.  All sterilization, cleanliness or 
decontamination procedures shall be solely the responsibility 
of the Author and shall be undertaken at the Author’s 
expense.  All indemnifications provided herein shall include 
JoVE’s attorney’s fees and costs related to said losses or 
damages.  Such indemnification and holding harmless shall 
include such losses or damages incurred by, or in connection 
with, acts or omissions of JoVE, its employees, agents or 
independent contractors. 
 
12.  Fees.  To cover the cost incurred for publication, JoVE 
must receive payment before production and publication the 
Materials. Payment is due in 21 days of invoice. Should the 
Materials not be published due to an editorial or production 
decision, these funds will be returned to the Author. 
Withdrawal by the Author of any submitted Materials after 
final peer review approval will result in a US$1,200 fee to 
cover pre-production expenses incurred by JoVE.  If payment is 
not received by the completion of filming, production and 
publication of the Materials will be suspended until payment is 
received. 
 
13.  Transfer, Governing Law.  This Agreement may be 
assigned by JoVE and shall inure to the benefits of any of 
JoVE’s successors and assignees.  This Agreement shall be 
governed and construed by the internal laws of the 
Commonwealth of Massachusetts without giving effect to any 
conflict of law provision thereunder.  This Agreement may be 
executed in counterparts, each of which shall be deemed an 
original, but all of which together shall be deemed to me one 
and the same agreement.  A signed copy of this Agreement 
delivered by facsimile, e-mail or other means of electronic 
transmission shall be deemed to have the same legal effect as 
delivery of an original signed copy of this Agreement.   
 
A signed copy of this document must be sent with all new submissions. Only one Agreement required per submission. 
 
AUTHOR: 
Name:   
Department:   
Institution:  
Article Title:  
 
Signature:   Date:  
 
 
Please submit a signed and dated copy of this license by one of the following three methods: 
1) Upload a scanned copy as a PDF to the JoVE submission site upon manuscript submission (preferred); 
2) Fax the document to +1.866.381.2236; or 
3) Mail the document to JoVE / Attn: JoVE Editorial / 17 Sellers St / Cambridge, MA 02139 
 
For questions, please email editorial@jove.com or call +1.617.945.9051. 
 
MS # (internal use):  
